Press Release

RepliCel CEO Provides Company Outlook

8 years ago May 24, 2017

A data-rich 2017 positions RepliCel for maturity through the next phase of its product development,...

United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

8 years ago Apr 24, 2017

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to...

Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date

8 years ago Apr 03, 2017

Interim trial results lead researchers to conclude that the injection of RCS-01 is not only...

RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

8 years ago Mar 27, 2017

First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration...

RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints

8 years ago Mar 13, 2017

Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategyVANCOUVER,...

RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization

8 years ago Mar 06, 2017

VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...

RepliCel Life Sciences Announces Re-pricing of Warrants

8 years ago Mar 05, 2017

VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector

8 years ago Feb 27, 2017

VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement

8 years ago Feb 23, 2017

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

8 years ago Feb 08, 2017

RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections...

Replicel Life Sciences Inc. Announces Brokered Private Placement

8 years ago Feb 06, 2017

VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors

8 years ago Feb 02, 2017

VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...

RepliCel CEO Provides 2017 Forecast

8 years ago Jan 04, 2017

After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion...

The Jake Brown Show

8 years ago Dec 06, 2016

Episode 10: SNY’s Taylor Rooks, Stylist Megan Wilson, Replicel’s Lee Buckler Released Dec 07, 2016...

RepliCel Life Sciences Announces Closing of Private Placement

8 years ago Oct 30, 2016

Completed Financing Positions RepliCel Through Upcoming Milestones VANCOUVER, BC – October 31, 2016 – RepliCel...

RepliCel Life Sciences Amends Terms of Private Placement

8 years ago Oct 06, 2016

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

RepliCel Announces Debt Settlement

8 years ago Sep 26, 2016

VANCOUVER, BC – September 27, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)...

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

8 years ago Sep 25, 2016

VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)...

RepliCel Life Sciences Announces Non-Brokered Private Placement

9 years ago Sep 13, 2016

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

Replicel Life Sciences Share Consolidation Approved

9 years ago Aug 08, 2016

Capital Structure Restructuring Expected to Lead to Financing and Milestones VANCOUVER, BC – August 9,...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.